Corus制药控股 CRBP 深 沪
已收盘 08-01 16:00:00 美东时间
9.31
+0.040
+0.43%
华盛通- 最 高9.67
- 今 开9.10
- 成交量 12.23万股
- 最 低 9.095
- 昨 收 9.27
- 总市值 1.14亿
- 52周最高 61.89
- 市盈率 静 --
- 换手率 1.00%
- 52周最低 4.64
- 委 比 83.33%
- 总股本 1223.68万
- 历史最高 323.40
- 量 比 0.78
- 振 幅 6.20%
- 历史最低 3.00
- 每 手 1
- 风险率 16.07%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Corbus Pharmaceuticals Announces That An Abstract On Updated Clinical Data From Its Phase 1/2 Clinical Study Of CRB-701 Has Been Accepted For Presentation As A Poster At The European Society For Medical Oncology Congress 2025, October 17-21, 2025 In Berlin, Germany
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, announced today that an abstract on updated clinical data from its Phase 1/2 clinical study conducted in the
07-30 20:02
Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress
Corbus Pharmaceuticals announced that updated clinical data for CRB-701 (SYS6002) from its Phase 1/2 study has been accepted for presentation at the 2025 ESMO Congress in Berlin. The study evaluates the safety, pharmacokinetics, and efficacy of CRB-701, a next-generation Nectin-4-targeting antibody-drug conjugate, in patients with solid tumors. Part A dose escalation assessed four doses, with ongoing dose optimization and expansion in HNSCC, cerv...
07-30 12:00
朱嘉明：稳定币的深层逻辑与未来图景
朱嘉明在“稳定币的未来”研讨会上分析了稳定币的历史演变及其对现代货币制度的影响。他认为稳定币可分为古典和现代两个阶段，古典稳定币基于贵金属或美元与黄金挂钩，而现代稳定币则结合区块链技术，分为抵押型和算法型。稳定币作为加密货币扩张的必然产物，正在重塑货币理论及数字经济格局。朱嘉明指出，美国正构建以比特币、稳定币和相关法案为核心的“三位一体”平行货币体系，而中国需探索央行数字货币与稳定币的协同路径。稳定币不仅提升美元竞争力，也为普惠金融提供了创新工具。
07-24 13:54
GENIUS 法案落地 我们该如何审慎对待稳定币叙事？
美国众议院通过三项加密相关立法，其中GENIUS法案即将生效，标志美国首次为稳定币确立国家级监管框架。全球主要经济体加速合规框架设计，稳定币从加密圈边缘议题跃升为国家战略重点。稳定币市场长期由USDT和USDC主导，新兴项目如PayPal和USD1推动其职能扩展至Web2和实体经济场景。合规要求增加，未来增长潜力在于替代传统美元账户。稳定币发展将牵动货币主权和地缘秩序，成为国际博弈焦点。
07-21 14:15
Genius 法案落地：我们该如何审慎对待稳定币叙事
美国众议院通过三项加密法案，GENIUS法案即将生效。稳定币迎来国家级监管框架，迈向主流金融体系，全球主要经济体加速立法支持。美国放弃CBDC，扶持私营稳定币，将影响全球监管设计。市场规模增长，USDT和USDC主导，新兴项目拓展应用场景。合规要求增加，稳定币面临进入Web2和实体经济的挑战，未来潜力巨大但需应对复杂博弈。货币发行的权力属性意味着稳定币将进一步影响地缘经济格局。
07-18 11:17
Cannabis Stock Gainers And Losers From July 16, 2025
GAINERS: 4Front Ventures (OTC:FFNTF) shares closed up 33.33% at $0.00 Blueberr...
07-17 04:32
【美股盤前】川普的巴西關稅政治化！達美航空漲12%，因螞蟻支持穩定幣Circle升4%，台積電二季度營收超預期，稀土股MP暴漲
TradingKey - 7月10日週四美股盤前，比特幣和輝達股價創新高之後，投資人權衡川普對巴西征收高達50%關稅和關稅政治化影響，標普500指數和納指100期貨盤前走平。達美航空恢復全年業績指引，預告本季和全年利潤高於預期打破市場對航空股擔憂，達美航空盤前大漲12%，帶動美國航空、阿拉斯加航空上漲4%，多個航空股走高。MP Materials與五角大樓達成數十億美元協議，MP大漲40%，帶動稀土概念股上揚。
07-10 12:19
Bullish Sentiment Across The Cannabis Space - Check Full Movers For July 9, 2025
GAINERS: Elixinol Wellness (OTC:ELLXF) shares closed up 490.50% at $0.02 1933 ...
07-10 04:30
Marijuana Stock Movers For July 2, 2025
GAINERS: Flower One Hldgs (OTC:FLOOF) shares closed up 900.00% at $1e-05 4Fron...
07-03 04:31
Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
Corbus Pharmaceuticals has initiated the multiple ascending dose (MAD) portion of its Phase 1 trial for CRB-913, a peripherally restricted CB1 inverse agonist for obesity treatment. The MAD study, scheduled to complete in Q3 2025, follows the single ascending dose (SAD) study, which showed no treatment-related neuropsychiatric events. The company plans to launch a Phase 1b dose-range finding study in obese individuals later this year. CRB-913 is ...
06-30 12:00
